Welcome to Blood Cancer United Newsroom
Get the latest news about how we are creating a world without blood cancers—and improving the quality of life of patients and their families.
News
FDA Approval Increases Access to a Follicular Lymphoma Immunotherapy
The FDA approves Lunsumio VELO™, a one-minute injection for relapsed follicular lymphoma, showing strong response rates and improved patient access.
News
Chief Executive Officer of BDO USA to Receive 2026 James L. Eichberg Lifetime Achievement Award
Blood Cancer United ®, formerly The Leukemia & Lymphoma Society, has named Mr. Wayne Berson, Chief Executive Officer of BDO USA, the recipient of the …
News
FDA Expands Use of Targeted Therapy for Most Common Leukemia in Adults
The FDA this week approved pirtobrutinib (Jaypirca®) for the treatment of chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) in ad…
News
FDA Approves First CAR T-Cell Immunotherapy for Marginal Zone Lymphoma
Liso-cel (Breyanzi®) is now approved to treat five types of blood cancer
News
Major Research Funders Team Up to Accelerate a Cure for Follicular Lymphoma
Blood Cancer United and IFLI are creating a research community to drive investment, advance technology and accelerate new treatments.
News
Blood Cancer United, formerly The Leukemia & Lymphoma Society, Announces New Funding for Lifesaving Cancer Breakthroughs
With the latest funding round, Blood Cancer United’s cumulative research funding tops $2 billion, continuing to help increase survival rates and impro…
News
Blood Cancer United Showcases Bold Research and Vision at 2025 ASH Annual Meeting
Data from Master Clinical Trials—focused on transforming care for patients with acute myeloid leukemia—will be presented at ASH.
News
FDA Approves Targeted Immunotherapy for Adults with Follicular Lymphoma
“Although we are making great progress in treating follicular lymphoma, it remains incurable, and we need new treatments like epcoritamab in this chem…
News
FDA approves new drug to treat advanced AML in adults
Blood Cancer United® funding supported menin inhibitor drugs, including ziftomenib, at every stage of scientific development.
For all media-related inquiries and interview requests please email
mediarelations@bloodcancerunited.org
A Blood Cancer United representative will respond as soon as possible.
